Healthcare / Medical Instruments & SuppliesKSE
$45450.00
-900.00 (-1.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 17%
FCF escenarios
weak_data · normalized FCF $14.8B · quality 41.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$392.0B
P/E
23.4x
↑EV/EBITDA
10.1x
↓ROE
2.9%
↑Gross Margin
62.9%
↑Debt/Equity
0.51
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-0.9%
FCF CAGR
—
FCF margin
-11.6%
FCF / Net income
-2.46x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $346.45B · net income $16.41B · FCF $-40.32B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $346.45B | $346.45B | $407.81B | $393.19B | $355.87B |
| Net Income | $16.41B | $16.41B | $72.71B | $96.52B | $86.07B |
| EBITDA | $58.97B | $58.97B | $126.72B | $162.80B | $144.14B |
| EPS | 1903.00 | 1903.00 | 8431.00 | 11193.00 | 9980.00 |
| Gross Margin | 62.9% | 62.9% | 63.8% | 70.9% | 73.3% |
| Operating Margin | 18.5% | 18.5% | 24.2% | 35.2% | 35.3% |
| Net Margin | 4.7% | 4.7% | 17.8% | 24.5% | 24.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.51 | 0.51 | 0.46 | 0.45 | 0.56 |
| Current Ratio | 1.50 | 1.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-40.32B | $-40.32B | $14.81B | $20.84B | $-7.10B |
| Returns | |||||
| ROE | 2.9% | 2.9% | 13.1% | 20.8% | 23.0% |
| Valuation | |||||
| P/E | 23.41 | 23.41 | 8.07 | 12.26 | 8.80 |
| EV/EBITDA | 10.09 | 10.09 | 5.87 | 8.02 | 6.20 |
| P/B | 0.68 | 0.68 | 1.06 | 2.55 | 2.03 |
| Growth & Yield | |||||
| Revenue Growth | -15.0% | -15.0% | 3.7% | 10.5% | — |
| EPS Growth | -77.4% | -77.4% | -24.7% | 12.2% | — |
| Dividend Yield | 1.3% | 1.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
28.4%
EPS terminal req.
$4032.93
Spread vs growth
-105.9%
5Y implied EPS CAGR
20.7%
EPS terminal req.
$4879.85
Spread vs growth
-98.2%
10Y implied EPS CAGR
15.2%
EPS terminal req.
$7859.04
Spread vs growth
-92.7%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.5%
Start / end P/E
7.4x → 23.4x
EPS bridge
8431.00 → 1903.00
Residual
-166.7%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.